J Bone Jt Infect 2020; 5(1):1-6. doi:10.7150/jbji.36923

Research Paper

Streptococcus bovis Hip and Knee Periprosthetic Joint Infections: A Series of 9 Cases

Jeremy C. Thompson1, Ashton H. Goldman1, Aaron J. Tande2, Douglas R. Osmon1,2, Rafael J. Sierra1 Corresponding address

1. Department of Orthopedic Surgery
2. Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Thompson JC, Goldman AH, Tande AJ, Osmon DR, Sierra RJ. Streptococcus bovis Hip and Knee Periprosthetic Joint Infections: A Series of 9 Cases. J Bone Jt Infect 2020; 5(1):1-6. doi:10.7150/jbji.36923. Available from http://www.jbji.net/v05p0001.htm

File import instruction

Abstract

Introduction: Prosthetic joint infection (PJI) due to Streptococcus bovis group (SBG), specifically S. bovis biotype I (S. gallolyticus), is rare and associated with colorectal carcinoma. Little has been published regarding SBG PJI. We analyzed nine cases of SBG PJI at our institution, the largest series to date.

Methods: The medical records of patients diagnosed with SBG PJI between 2000-2017 were reviewed. Patients were followed until death, failure, or loss to follow-up. Mean follow-up was 37 months (range 0.5-74 months).

Results: Nine PJI in 8 patients with mean prosthesis age at diagnosis of 8 years (range 4 weeks-17 years) were identified. The median duration between symptom onset and treatment was 38 weeks (range 0.3 weeks-175 weeks). 8/9 had their PJI eradicated with treatment based on acuity of symptoms. Acute PJI (2) was treated with DAIR, and chronic PJI (7) was treated with 2-stage revision arthroplasty. 1 PJI with chronic PJI developed recurrent infection after initial treatment. All patients received post-operative IV antibiotics. 7/8 patients received Ceftriaxone. Three patients received lifelong oral antibiotics. 7/8 patients underwent colonoscopy. 5/7 patients were found to have polyps following PJI diagnosis with one carcinoma and two dysplastic polyps. The two patients without polyps had identifiable gastrointestinal (GI) mucosal abnormality: tooth extraction prior to symptom onset and diverticulosis on chronic anticoagulation.

Conclusion: SBG PJI is typically due to hematologic seeding. Colonoscopy should be pursued for patients with SBG PJI. Surgical treatment dictated by infection acuity and 6-week course of Ceftriaxone seems sufficient to control infection.

Introduction

Periprosthetic joint infection (PJI) is a major complication with an incidence of 0.3% to 4% after primary total hip arthroplasty (THA) and 0.4% to 3.9% for primary total knee arthroplasty (TKA) [1-6]. Several risk factors for the development of PJIs are well-known and include an immunocompromised state, diabetes mellitus, poor nutrition, and wound complications, among others [3-5, 7]. The most common PJI pathogens are Staphylococcus aureus and coagulase-negative staphylococci; however, there are other less common PJI-causing bacteria that have specific treatment, diagnostic, and prognostic implications [8, 9].

The Streptococcus bovis group (SBG) is an uncommon cause of PJI. Previous reports have shown a strong association between SBG bacteremia and concomitant colorectal carcinoma [10, 11]. With the development of more refined identification methods, the nomenclature and disease associations of SBG have been updated to show association between specifically S. bovis biotype I (S. gallolyticus subsp. gallolyticus) and colorectal cancer [12-14]. However, little has been published regarding SBG septic arthritis, and even less has been reported regarding SBG PJI [15-20]. The purpose of this paper is to report one institution's experience with SBG PJI and answer the following questions: 1. what is the proportion of SBG PJI to all PJI, (2) what is the relationship between SBG PJI and any potential sources including colonic/rectal malignancy, and (3) what are the outcomes of surgically treated SBG PJIs.

Methods

After IRB approval (IRB # 18-000453, 2/8/2018), we identified all cases of SBG PJI from our institutional PJI registry that includes all hip and knee PJI diagnosed and/or treated at our institution. Cases of SBG between January 1, 2000 and May 1, 2017 were identified. All patients over 18 years of age who underwent initial surgical management of a SBG PJI at our institution were included. Detailed patient information was abstracted from the medical record. SBG PJI was diagnosed based on Musculoskeletal Infection Society (MSIS) criteria and retrospectively confirmed using the proposed 2018 MSIS criteria [21, 22]. Medical and surgical therapies were not standardized and were performed at the discretion of the treating physicians. Patients were followed after treatment for recurrence of infection or death. Treatment failure was determined using previously published criteria developed through the Delphi process [23]. Acute PJ I was defined as infectious symptom duration less than 3 weeks or diagnosis and/or symptom onset within 4 weeks from arthroplasty. Chronic PJ I was defined as infectious symptoms during a period greater than what is noted above. The data are reported using standard summary statistics, including means for continuous variables, and counts and percentages for categorical variables. Descriptive statistics were analysed using JMP, Version 9.0.1 (SAS Institute Inc.).

Results

There was a total of 2,459 PJIs in 1,930 patients during the study period treated at our institution. The nine cases of SBG PJI accounted for 0.4% of the total PJI at our institution over the 18-year study period. Nine SBG PJI (8 patients) were included in our patient cohort. The biotype of SBG was known in one patient (S. gallolyticus). One patient had simultaneous bilateral PJI. The average age at time of PJI diagnosis was 75 years old (range 65 - 95 years), and the average BMI was 32 kg/m2 (range 25 - 35 kg/m2 (Table 1). All patients obtained blood cultures at time of diagnosis of PJI, none of which returned positive. No patient received antibiotics within 3 months of obtaining blood or joint fluid culture. 2 of 8 patients underwent echocardiogram after PJI diagnosis with 1 patient showing signs of endocarditis. This patient had a known history of native valve SBG endocarditis treated with a 6 week courses of ceftriaxone and ertapenem followed by porcine valve replacement after resolution of endocarditis 11 months after diagnosis. He developed simultaneous bilateral knee S. gallolyticus PJI 6 months after heart valve replacement.

 Table 1 

Demographic data related to 9 cases of SBG PJI.

PJI #SexAge at time of PJIBMIAffected JointCo-Morbidities
1Female6532Left HipNone
2Female95UnknownRight Kneediabetes mellitus type 2, chronic kidney disease, hypertension, congestive heart failure, coronary artery disease
3Male7534Left Hiphypertension, coronary artery disease, peripheral vascular disease
4Male7230Left HipAtrial fibrillation (Coumadin), EtOH use, Prior bariatric surgery, previous GI bleed, diverticulosis
5Female7931Right KneeNone
6Male7035Left KneePrior S. gallolyticus native valve endocarditis, diabetes mellitus type 2, Prior venous thromboembolism (Coumadin), Tobacco use, chronic kidney disease, peripheral vascular disease, coronary artery disease, Prior Diskitis
7"""Right Knee"
8Female6931Right KneeHistory of bariatric surgery, diabetes mellitus type 2, Hx venous thromboembolism, iron-deficient anemia, Hypothyroidism
9Female8125Left Hipcoronary artery disease, atrial fibrillation (pacemaker), congestive heart failure, Depression, Liver hemangiomas, gastrointestinal reflux disease
Mean (Range)37.5% Male75 (65 - 95)32 (23 - 35)44.4% Hips-----

Seven of the 8 patients underwent colonoscopy with biopsy after diagnosis of SBG PJI with one patient deferring colonoscopy due to comfort care management. Of the 7 patients undergoing colonoscopy, 1 patient was diagnosed with colorectal carcinoma, 1 patient was found to have high grade dysplastic polyps, 1 patient had low-grade dysplastic polyps, and 2 patients were found to have adenomatous polyps without dysplasia (Table 2). Therefore 5 of 7 patients had colorectal processes at the time of the SBG PJI, while 2 patients had no evidence of polyps or carcinoma on colonoscopy. The 2 patients without GI tract neoplasm identified on colonoscopy had other mucosal abnormalities: one patient underwent tooth extraction 5 weeks prior to onset of symptoms, and the other patient was found to have diverticulosis, on chronic anticoagulation for atrial fibrillation, a history of a GI bleed, and had a history of bariatric surgery. Within the subset of patients with colonic neoplasm, multiple patients were found to have additional sources of GI mucosal abnormality and/or bacteraemia. These abnormalities include diverticulosis (3), history of GI bleed (3), prior bariatric surgery (2), liver hemangioma (1), arteriovenous malformation (1), candida esophagitis (1), and history of SBG endocarditis and subsequent porcine cardiac valve replacement.

The mean age of the prosthesis before surgical treatment of PJI was 8 years (4 weeks - 17 years). Two acute haematogenous PJIs were treated with irrigation, debridement, and polyethylene exchange (DAIR). The mean duration of symptoms before DAIR was 3.5 days. The seven remaining PJI presenting as chronic infection were treated with a 2-stage revision with plans for subsequent reimplantation (Table 3). The mean duration of symptoms before 2-stage surgical treatment was 38 weeks (5 weeks - 175 weeks). One patient (with simultaneous bilateral knee PJI) elected to have his reimplantation performed closer to home and was subsequently lost to follow- up. Four of the remaining 5 PJI subsequently went on to reimplantation while 1 patient opted to keep the articulating spacer as it was functioning well and had no evidence of reinfection. The mean time to re- implantation was 48 weeks (range 10 - 109 weeks). All patients received IV antibiotics, with the treatment details presented in Table 2. Ceftriaxone (6-week course) was the most commonly used IV antibiotic with only 1 patient using an alternative (ertapenem due to side effects). Three total patients were recommended lifelong antibiotic suppression. The two patient receiving DAIR treatment for acute PJI and the one patient with chronic PJI deemed a treatment failure were given lifelong oral antibiotic suppression at the discretion of the treating physicians.

Of the 7 patients who underwent planned 2-stage revision arthroplasty, one joint sustained a subsequent infection with another organism. This patient was deemed a treatment failure. She required one return trip to OR for irrigation & debridement two separate return trips to OR for revision spacer placement before definitive re-implantation. This patient presented as a 69-year-old female with past history of prior bariatric surgery with resultant malnutrition/hypoalbuminemia, obesity, and diabetes mellitus that underwent primary right TKA for continued pain after non-operative management of patella fracture and primary knee osteoarthritis. Her initial surgery was complicated by postoperative arthrofibrosis for which she underwent manipulation under anaesthesia at 2 months postoperatively. She continued to have chronic right knee pain and underwent revision TKA for loosening one year later. While she did have a positive bone scan before this revision TKA, cultures were not obtained at that time. She reported recurrence of knee pain after a 6-month pain free period. She managed this pain conservatively for 3.5 years before presenting to Mayo Clinic. Aspiration of the knee was then obtained which revealed purulent fluid, cell count of 15,390, and 97% polynuclear cells. Cultures returned as pan-sensitive S. bovis. Further speciation was not available. Due to its association with colorectal cancer, she underwent colonoscopy which returned with multiple tubulevillous polyps and associated low-grade dysplasia. She subsequently underwent placement of antibiotic spacer and was started on IV ertapenem (ceftriaxone deferred due to gastric irritability) and oral TMP-SMX. She subsequently developed right knee drainage and sinus tract formation for which she returned the operating room at 2 weeks post-op for I&D and sinus tract excision. She was maintained on IV ertapenem, and she was placed in a long leg cast after this procedure. Tissue cultures at this time were negative for causal organism. Unfortunately, 1 month from this I&D, she presented with recurrent wound drainage. Serum ESR and CRP at this time were 45 mm/1st hr and 21 mg/dL respectively. Aspiration revealed 2,588 nucleated cells and 47% neutrophils. The decision was made to return to the operating room for exchange of antibiotic cement spacer and antibiotics were switched to ceftriaxone for 10 weeks. 3 months after this surgery, she again presented with a persistently draining anterior right knee. The decision was made for repeat antibiotic cement spacer placement with assistance from plastic surgery for pedicled gastrocnemius flap coverage and split thickness skin graft for wound coverage. Tissue cultures at this time were negative for causal organism. IV antibiotics were changed to piperacillin-tazobactam for 3 months after surgery. At a follow-up visit 6 weeks from this surgery, she again was found to have a draining, non-healing right knee wound. She again returned to the operating room for exchange of her antibiotic cement spacer. Tissue cultures at this time were positive for ticarcillin-clavulanate and ceftazidime-resistant Stenotrophomonas Maltophilia. She was thus given the following antibiotics simultaneously over a 4-week period: 7-day course of IV daptomycin, 4-week course of ertapenem, and 2-week course of oral levofloxacin followed by 2-week course of TMP-SMX. She denied pain post-operatively but maintained mildly elevated inflammatory markers. An indium scan was performed which returned negative for signs of infection. Because she was doing well clinically off of antibiotics, the decision was made to perform right knee reimplantation with hinged prosthesis 81.1 weeks after prior cement exchange (108.9 weeks from 1st spacer placement). Before re-implantation, she had a repeat colonoscopy which identified an arteriovenous malformation (AVM) in the ascending colon as well as multiple pedunculated adenomatous polyps without dysplasia. She has been on lifetime cefadroxil since this operation. Inflammatory markers have since normalized and repeat aspiration was within normal limits at last follow-up 21 months after her last surgery.

Discussion

While SBG, specifically S. Bovis biotype I (S. gallolyticus) infection such as bacteremia and/or infective endocarditis have been shown to be correlated with colorectal cancer, little has been published regarding S. bovis PJI. In our review, SBG was responsible for 0.4% of all PJI at our institution over the study period. In our study of 9 cases of SBG PJI, we found one case of colorectal cancer and 2 cases of dysplastic polyps. Additionally, all 8 patients were found to have at least one GI mucosal abnormality predisposing to bacterial translocation to the bloodstream.

 Table 2 

Treatment Outcomes, Colonoscopy data, and GI mucosal risk factors related to SBG PJI in the current cohort.

Patient #Symptom DurationSurgical ManagementAntimicrobial TherapyReturn to OR?OutcomeFollow- up DurationColonoscopy ResultsGI Comorbidities/ FindingsOther
144 weeks2-StageIV Ceftriaxone (6 weeks) `NoReimplantation at 55 weeks74 monthsTubulovillous Polyps - High grade dysplasiaNoneDiagnosed with ovarian cancer after resolution from PJI
21 weekPoly ExchangeIV Ceftriaxone (2 weeks); Oral Cephalexin (indefinite)NoDeath (unknown cause)0.5 monthsDeferredDeferredComfort care. Cause of death unknown
312 weeks2-StageIV Ceftriaxone (6 weeks)NoReimplantation at 10 weeks68 monthsColorectal carcinoma (T1N0M0)DiverticulosisN/A
42 daysPoly ExchangeIV Ceftriaxone (6 weeks); Oral Penicillin VK (indefinite)NoClear of infection and downtrending ESR/CRP51 monthsIndeterminate* (*Poor prep; also CT found indeterminate)Diverticulosis; Prior bariatric surgeryPre-operative inguinal hernia s/p repair
55 weeks2-StageIV Ceftriaxone (6 weeks)NoDelayed wound closure; reimplantation at 10 weeks44 monthsCleanNoneTooth extraction w/ Amoxicillin ppx 5wk prior to onset; Delayed wound healing without infection - Tx w/ wet/dry dressing
6*10 weeks2-StageIV Ceftriaxone (6 weeks)NoReimplantation at OSH; Clear of infxn at last follow-up prior to reimplantation (13 months)13 monthsAdenomatous polyp, Candida EsophagitisDiverticulosis; Candida esophagitisPre-operative endocarditis; Smoker (1PPD); History of GI bleed
7*10 weeks2-Stage"No"""""
8175 weeks2-StageIV ertepenem; Cefadroxil (indefinite)Yes(1) Superficial I&D, (2-3) Revision abx cement spacer x 2 prior to final reimplatntation (109 weeks after dx); Clear of infection at last f/u46 monthsTubulovillous Polyp (low grade dysplasia); AVMPrior bariatric surgeryHistory of rectal bleed (anticoagulation)
911 weeks2-StageIV ceftriaxone (6 weeks)NoReimplantation deferred (functioning spacer)22 monthsAdenomatous Polyp, DiverticulosisDiverticulosis; Liver hemangiomas, History of choledocolithiasisChronic anticoagulation and history of GI bleeds
38 weeks (2 days - 175 wks)78% with 2-Stage89% with IV Ceftriaxone
89% with ≥ 6 weeks IV Tx
33% with chronic suppression
11% failure (1 of 9)Time to reimplantation 48 weeks (range 10 - 109 weeks).37 months (0.5 - 74)14% colorectal cancer (1 of 7)
29% dysplastic Polyps (2 of 7)
14% adenomatous polyps only (1 of 7)
 Table 3 

Infection data of the current series.

Patient #Prosthetic Joint (Revisions)Revision SurgeriesClinical PresentationMicrobiologyAspirate (Cells, % PMN)Age of Prosthesis at time of infection
1Left HipRevised x 3 (wear), Revised x 1 (loosening)Pain, fever, erythema, sinus tract x 44 weeksAspirate: (+) SBG -- Tissue: (+) SBG, S. virdans10,625 cells, 98% PMN2 years
2Right KneeNoneChest pain, shortness of breath, knee pain x 1 weeksAspirate: (+) SBG27,612 cells, 85% PMNUnknown (unknown date of primary)
3Left HipRevised x 1 (wear); Revised x 2 (loosening)Pain x 12 weeksAspirate & Tissue: (+) SBG28,281 cells, 97% PMN4 years
4Left HipRevision x 1 (progression of Hemi OA); Revision x 1 (periprosthetic fracture)Pain, Fever x 2 daysAspirate & Tissue: (+) SBG64,001 cells, 97% PMN4 weeks
5Right KneeNonePain, loosening x 5 weeksAspirate & Tissue: (+) SBG98,164 cells, 97% PMN17 years
6*Left KneeNonePain, Sinus tract x 10 weeksAspirate: (+) SBG -- Tissue (-)213,576 cells, 97% PMN12 years
7*Right KneeNonePain x 10 weeksAspirate: (+) SBG -- Tissue (+) P acnes321,380 cells, 98% PMN12 years
8Right KneeRevision x 1 (loosening)Pain, Swelling x 175 weeksAspirate: (+) SBG -- Tissue (-)15,390 cells, 97% PMN1 yr
9Left HipNonePain x 11 weeksAspirate & Tissue: (+) SBG27,248 cels, 97% PMN16 yrs
Mean44.4% with prior revision30 weeks of symptoms (0.3 - 175)100% aspirate (+) SBG
55.5% Tissue (+) SBG
22.2% additional pathogen
89,586.3 Cells (10,625 - 321,380)
95.9% PMN (85% - 98%)
8 yrs (4 weeks - 17 years)

Colorectal cancer is currently the fourth most common cancer in the United States. While the 5-year survival rate of those with colorectal cancer is only 65%, it has been shown that early treatment of polyps, diagnosis, and definitive treatment has a positive impact of survival [24, 25]. The SBG group are members of the Group D streptococcus family and are Gram-positive cocci that can be part of the normal GI flora in 5-16% of adults [10, 11]. Furthermore, it has been shown that colorectal carcinoma alters the native gut microbiosis which promotes Streptococcus gallolyticus proliferation[26]. It has been suggested that this bacterium releases inflammatory proteins which stimulate chronic inflammation, inhibit apoptosis, and increase angiogenesis which may lead to neoplasm formation [27, 28]. Therefore SBG PJI may play a role in the early diagnosis of colorectal cancer.

Prior to this case series, the authors were able to identify only 6 case reports of SBG PJI [1, 2, 8, 15-20, 29]. Four of the reported 6 cases had concomitant colorectal cancer, while the other cases had endocarditis or had premalignant polyps [15-20]. One patient was found to have colorectal cancer, and 2 patients were found to have premalignant polyps. In other disease states, the association between colorectal cancer and SBG infection appears to be most closely associated with the SBG biotype I (S. gallolyticus subspecies gallolyticus) [13]. Subspeciation was identified in only 1 previous case report (S. gallolyticus) and this patient was found to have associated colonic malignancy[18]. In our study, the subspecies or SBG biotype causing infection for our patients was unknown in all but 1 patient (bilateral knee PJI) who was found to have S. gallolyticus PJI. Despite this lack of subspecies information and despite our lower rate of diagnosis of definitive colonic malignancy than previously published, there does still appear to be a correlation between GI mucosal abnormalities and SBG PJI.

There was one patient with SBG PJI requiring return to the operating room for spacer exchange prior to reimplantation due to a recalcitrant infection. It should be noted that this patient received a dissimilar antibiotic and has multiple risk factors for PJI as noted above. She has since been reimplanted and is on life-long suppression. Seven of 8 patients with available follow-up had their PJI eradicated with DAIR or 2-stage treatment depending on the acuity of their PJI. Acute PJI was treated with DAIR, and chronic PJI was treated with 2-stage revision arthroplasty. The 2 patients with acute PJI treated with DAIR received lifelong antibiotic suppression due to one patient deferring prolonged IV antibiotics due to comfort care management and the other patient due to a history of multiple revisions. This suggests that S.bovis PJI can be treated successfully with DAIR vs. 2-stage treatment and a 6-week course of appropriate IV antibiotics with additional antibiotics at the discretion of the treating physicians.

The major limitations to our study are inherent to with observational, retrospective nature. The small sample size is a function of the low incidence of disease. However, our institutional PJI registry has allowed us to retrospectively capture these cases for review and create the largest case series to date. Since our data was collected from a single tertiary referral medical center, there is potential for referral bias. This also contributed to a high variation in follow-up as multiple patients elected to follow-up at their respective outside facilities. Also, as previously mentioned, full speciation of the SBG subspecies was not obtained and/or recorded for all but 1 of the patients in the series. Information regarding the specific SBG subspecies would no doubt add to the association of colorectal cancer, GI mucosal abnormality, and PJI.

After review and analysis of our patient cohort, SBG PJI is relatively uncommon and results from late hematogenous seeding. As the majority of cases showed sensitivity to Ceftriaxone, surgical treatment dictated by infection acuity and medical treatment consisting of a 6-week course of Ceftriaxone seems sufficient to control infection. Risk factors for GI mucosal breakdown, including colorectal cancer, could be identified for those patients that elected to undergo colonoscopy. This data supports obtaining a colonoscopy in patients diagnosed with SBG PJI. This study provides insight into one potential mechanism of late hematogenous PJI.

Acknowledgements

Members of the research team with associated roles are the following: Jeremy Thompson MD: Writing - Original draft, Lead; Ashton H. Goldman, MD: Writing - Original draft, Supporting; Aaron J. Tande, MD: Writing - Review and editing, Equal; Douglas R. Osmon, MD: Writing - Review and editing, Equal; Rafael J. Sierra, MD: Conceptualization, Writing - Review and editing, Equal.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Blom AW, Brown J, Taylor AH, Pattison G, Whitehouse S, Bannister GC. Infection after total knee arthroplasty. J Bone Joint Surg Br. 2004;86:688-91

2. Marculescu CE, Berbari EF, Cockerill FR 3rd, Osmon DR. Unusual aerobic and anaerobic bacteria associated with prosthetic joint infections. Clin Orthop Relat Res. 2006;451:55-63

3. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM. et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:e1-e25

4. Phillips JE, Crane TP, Noy M, Elliott TS, Grimer RJ. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. J Bone Joint Surg Br. 2006;88:943-8

5. Tande AJ, Palraj BR, Osmon DR, Berbari EF, Baddour LM, Lohse CM. et al. Clinical Presentation, Risk Factors, and Outcomes of Hematogenous Prosthetic Joint Infection in Patients with Staphylococcus aureus Bacteremia. Am J Med. 2016;129(221 e):11-20

6. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645-54

7. Willis-Owen CA, Konyves A, Martin DK. Factors affecting the incidence of infection in hip and knee replacement: an analysis of 5277 cases. J Bone Joint Surg Br. 2010;92:1128-33

8. Sharma D, Douglas J, Coulter C, Weinrauch P, Crawford R. Microbiology of infected arthroplasty: implications for empiric peri-operative antibiotics. J Orthop Surg (Hong Kong). 2008;16:339-42

9. Stefansdottir A, Johansson D, Knutson K, Lidgren L, Robertsson O. Microbiology of the infected knee arthroplasty: report from the Swedish Knee Arthroplasty Register on 426 surgically revised cases. Scand J Infect Dis. 2009;41:831-40

10. Aymeric L, Donnadieu F, Mulet C, du Merle L, Nigro G, Saffarian A. et al. Colorectal cancer specific conditions promote Streptococcus gallolyticus gut colonization. Proc Natl Acad Sci U S A. 2018;115:E283-E91

11. Klein RS, Recco RA, Catalano MT, Edberg SC, Casey JI, Steigbigel NH. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med. 1977;297:800-2

12. Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis. 2011;53:870-8

13. Dekker JP, Lau AF. An Update on the Streptococcus bovis Group: Classification, Identification, and Disease Associations. J Clin Microbiol. 2016;54:1694-9

14. Ruoff KL, Kunz LJ. Use of the Rapid STREP system for identification of viridans streptococcal species. J Clin Microbiol. 1983;18:1138-40

15. Apsingi S, Kulkarni A, Gould KF, McCaskie AW. Late Streptococcus bovis infection of knee arthroplasty and its association with carcinoma of the colon: a case report. Knee Surg Sports Traumatol Arthrosc. 2007;15:761-2

16. Emerton ME, Crook DW, Cooke PH. Streptococcus bovis-infected total hip arthroplasty. J Arthroplasty. 1995;10:554-5

17. Hernandez-Vaquero D, Cuervo-Olay MC, Suarez-Vazquez A. Association of Streptococcus bovis haematolgenous infection in total knee replacement with large intestine carcinoma. Orthopedics. 2008;31:92

18. Liddle AD, Abram S, Iyer S, Andrade AJ. Streptococcus gallolyticus prosthetic joint infection associated with undiagnosed colonic malignancy. Knee Surg Sports Traumatol Arthrosc. 2012;20:1069-70

19. Nagy MT, Hla SM, Keys GW. Late Streptococcus bovis infection of total knee replacement complicated by infective endocarditis and associated with colonic ulcers. BMJ Case Rep. 2013. 2013

20. Vince KG, Kantor SR, Descalzi J. Late infection of a total knee arthroplasty with Streptococcus bovis in association with carcinoma of the large intestine. J Arthroplasty. 2003;18:813-5

21. Parvizi J, Gehrke T. Definition of Periprosthetic Joint Infection. The Journal of Arthroplasty. 2018;29:1331

22. Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF. et al. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. J Arthroplasty. 2018;33(e2):1309-14

23. Diaz-Ledezma C, Higuera CA, Parvizi J. Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus. Clin Orthop Relat Res. 2013;471:2374-82

24. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut. 2001;48:812-5

25. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS. et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329:1977-81

26. Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P. et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One. 2011;6:e16393

27. Biarc J, Nguyen IS, Pini A, Gosse F, Richert S, Thierse D. et al. Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis). Carcinogenesis. 2004;25:1477-84

28. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem. 2007;42:93-126

29. Dallaverde Neto E. Septic arthritis due to Streptococcus bovis in a patient with liver cirrhosis due to hepatitis C virus: case report and literature review. Revista brasileira de reumatologia. 2011;51:520-3

Author contact

Corresponding address Corresponding author: Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. Phone: (507) 284-2884; Fax: (507) 266-4234


Received 2019-5-22
Accepted 2019-9-15
Published 2020-1-1